Cite
HARVARD Citation
Ray, A. et al. (n.d.). P306 MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects. Journal of Crohn's and colitis. pp. S333-S335. [Online].